Nihanthy D. Sreenath

Kolkata, WB, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Leveraging Social Media for Oncology Education and Practice: Perspective From Low- and Middle-Income Countries.

Leveraging Social Media for Oncology Education and Practice: Perspective From Low- and Middle-Income Countries.

Journal: JCO global oncology

Published: June 24, 2026

Clinical Impact of Integrating RNA-Based Next-Generation Sequencing Into the Diagnostic Evaluation of Soft Tissue Sarcomas: Insights From a Single-Center Multidisciplinary Workflow.

Clinical Impact of Integrating RNA-Based Next-Generation Sequencing Into the Diagnostic Evaluation of Soft Tissue Sarcomas: Insights From a Single-Center Multidisciplinary Workflow.

Journal: JCO global oncology

Published: March 11, 2026

Bold Brushstrokes, Bravery, and the Bat-Fan: The Girl Who Laughed in Color.

Bold Brushstrokes, Bravery, and the Bat-Fan: The Girl Who Laughed in Color.

Journal: JCO global oncology

Published: February 20, 2026

Where the Borders Bleed: Festivals, Fragility, and the Footfall of a Young Soldier's Return.

Where the Borders Bleed: Festivals, Fragility, and the Footfall of a Young Soldier's Return.

Journal: JCO global oncology

Published: August 14, 2025

Treatments for unresectable hepatocellular carcinoma: insights from CheckMate 9DW.

Treatments for unresectable hepatocellular carcinoma: insights from CheckMate 9DW.

Journal: Lancet (London, England)

Published: May 19, 2025

A Good Innings - A Tale of Hope, Heartbreak, and Healing.

A Good Innings - A Tale of Hope, Heartbreak, and Healing.

Journal: The New England journal of medicine

Published: April 28, 2025

From Present to Future: The Shifting Paradigm of Advanced Hepatocellular Carcinoma.

From Present to Future: The Shifting Paradigm of Advanced Hepatocellular Carcinoma.

Journal: JCO oncology practice

Published: April 16, 2025

A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort.

A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort.

Journal: BMC cancer

Published: December 17, 2024

Showing 1-8 of 8

Last Updated: 09/26/2026